
|Videos|July 25, 2023
SUNSHINE and SUNRISE Trials in HS
Author(s)Renata Block, MMS, PA-C
An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
2
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
3
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
4
Why Mentorship Matters Most for Dermatology Trainees
5








































































